Loki Therapeutics – AWAKE™ Platform Technology

Chris Bradley, CEO of Loki Therapeutics discusses Loki’s proprietary AWAKE™ strategy that completely bypasses the major challenges faced by traditional immunotherapy approaches.  AWAKE reactivates and redirects pre-existing, life-long Memory T-cells created during childhood vaccination to target and eliminate cancer cells rather than training naïve T-cells against tumor antigens like traditional immunotherapy.

Chris Bradley is currently CEO and Founder of Loki Therapeutics, an immuno-oncology company focused on difficult to treat solid tumors. He was previously an Executive Director in Comcast NBC Universal’s strategic development division, where he worked on numerous healthcare-related projects. Prior to that, Chris was co-founder and CEO of Mana Health,a health data interoperability company. A son of two physicians, Chris learned from an early age that medical records provided immense amounts of data, but not the insights everyone had hoped for. This led to his realization that by combining medicine and computer science, one could potentially unlock the knowledge sealed within this morass of raw data, hopefully leading to more effective and efficient healthcare for patients and their families, on a massive scale. This realization became the foundation for Mana Health, an award-winning health data startup he co-founded out of graduate school. Chris is a nationally recognized thought leader and innovator and has contributed to interoperability conversations at the White House, the Office of the National Coordinator for Health IT and in other important venues. He holds a B.A. in Neuroscience and Cell Biology, and an M.S.in Computer Science.